TeSR™-AOF

cGMP, animal origin-free, stabilized, feeder-free maintenance medium for human ES and iPS cells
TeSR™-AOF

Animal origin-free, stabilized, feeder-free maintenance medium for human ES and iPS cells

1 Kit
Catalog # 100-0401
379 USD

Overview

Reduce risk and obtain more high-quality cells in your human pluripotent stem cell-derived (hPSC) cell therapy development with TeSR™-AOF, manufactured under relevant cGMPs. With no materials of animal or human origin to the secondary level of manufacturing, enjoy more straightforward traceability and enhanced viral safety compared to media that are only animal origin-free to the primary level of manufacturing.

Use TeSR™-AOF to consistently culture viral-safe, high-quality PSCs on a schedule that works for you—with whatever cell lines you choose. To enhance cell quality attributes, particularly during restricted feeds, critical medium components have been stabilized, including fibroblast growth factor 2 (FGF2; also known as basic FGF [bFGF]). As a result, TeSR™-AOF allows for both daily and restricted feeding schedules while maintaining cell quality and equivalent performance. See data.

TeSR™-AOF is compatible with a variety of culture matrices, including Corning® Matrigel® hESC-Qualified Matrix (Corning Catalog #354277), Vitronectin XF™ (Catalog #07180), and CellAdhere™ Laminin-521 (Catalog #77003).

No materials of animal or human origin are used in the manufacture of this medium or its components, to at least the secondary level of manufacturing. Each lot of TeSR™-AOF 20X Supplement that is used to prepare complete TeSR™-AOF medium is performance-tested in a culture assay using human pluripotent stem cells.

TeSR™-AOF is manufactured under relevant cGMPs, ensuring the highest quality and consistency for reproducible results. Learn more about quality and regulatory compliance at STEMCELL.
Advantages
⦁ ANIMAL ORIGIN-FREE
De-risk your choice of ancillary materials by selecting a medium with no animal raw materials to the secondary level of manufacturing
⦁ CONSISTENT CELL GROWTH
Supports high-quality colony morphology, robust attachment, and cell expansion
⦁ STABILIZED
Stabilized components, including FGF2, support high cell quality while allowing for alternate feeding schedules
Components
  • TeSR™-AOF Basal Medium, 475 mL
  • TeSR™-AOF 20X Supplement, 25 mL
Subtype
Specialized Media
Cell Type
Pluripotent Stem Cells
Species
Human
Application
Cell Culture, Expansion, Maintenance
Brand
TeSR
Area of Interest
Cell Therapy, Disease Modeling, Drug Discovery and Toxicity Testing, Stem Cell Biology
Formulation
Animal Origin-Free

Scientific Resources

Product Documentation

Document Type Product Name Catalog # Lot # Language
Document Type
Product Information Sheet
Product Name
TeSR™-AOF
Catalog #
100-0401
Lot #
All
Language
English
Document Type
Manual
Product Name
TeSR™-AOF
Catalog #
100-0401
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
TeSR™-AOF
Catalog #
100-0401
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
TeSR™-AOF
Catalog #
100-0401
Lot #
All
Language
English

Educational Materials (15)

Brochure
TeSR™-AOF Product Overview Flyer
Wallchart
Derivation and Applications of Human Pluripotent Stem Cells
Video
TeSR™-AOF: Designing a Product for the Future
1:18
TeSR™-AOF: Designing a Product for the Future
Video
How to Set Up an Assay with the hPSC Genetic Analysis Kit Experiment
8:33
How to Set Up an Assay with the hPSC Genetic Analysis Kit Experiment
Video
TeSR™-AOF Data Overview
13:08
TeSR™-AOF Data Overview
Webinar
Nature Research Round Table: Human Pluripotent Stem Cell Lines as Disease Models
17:30
Nature Research Round Table: Human Pluripotent Stem Cell Lines as Disease Models
Webinar
Human Pluripotent Stem Cells for the Treatment of Age-Related Macular Degeneration and Compliance Considerations for Clinical-Grade iPSCs
47:23
Human Pluripotent Stem Cells for the Treatment of Age-Related Macular Degeneration and Compliance Considerations for Clinical-Grade iPSCs
Webinar
Nature Research Round Table: hPSC Lines for Cell Therapies - Panel Discussion
29:03
Nature Research Round Table: hPSC Lines for Cell Therapies - Panel Discussion
Webinar
Nature Research Round Table: Retinal Cell Therapy Using Human Embryonic Stem Cells
19:35
Nature Research Round Table: Retinal Cell Therapy Using Human Embryonic Stem Cells
Webinar
Lost in Translation - Moving Your Research to Clinical Trials
59:01
Lost in Translation - Moving Your Research to Clinical Trials
Webinar
Considerations for High-Efficiency Genome Editing of Human Pluripotent Stem Cells
50:01
Considerations for High-Efficiency Genome Editing of Human Pluripotent Stem Cells
Webinar
Nature Research Round Table: Parkinson's Disease Therapy with Human Embryonic Stem Cells
24:46
Nature Research Round Table: Parkinson's Disease Therapy with Human Embryonic Stem Cells
Webinar
Quality by Design: Reagents and Support for hPSC-Derived Cell and Gene Therapies
39:33
Quality by Design: Reagents and Support for hPSC-Derived Cell and Gene Therapies
Webinar
Quality Control Guidelines for Clinical-Grade Human Induced Pluripotent Stem Cell Lines
1:13:44
Quality Control Guidelines for Clinical-Grade Human Induced Pluripotent Stem Cell Lines
Scientific Poster
Expansion of High-Quality Human Pluripotent Stem Cells (hPSCs) Using a Novel Animal Origin-Free and Stabilized hPSC Maintenance Medium
Load More Educational Materials

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Data

 hPSCs Maintained in TeSR™-AOF with Daily and Restricted Feed Schedules Exhibit Comparable Colony Morphology

Figure 1A. hPSCs Maintained in TeSR™-AOF with Daily and Restricted Feed Schedules Exhibit Comparable Colony Morphology

hPSCs were maintained on Vitronectin XF™ for five passages. Phase-contrast images were taken on day 7 after seeding. For restricted feeds, hPSCs were fed with a double volume (4 mL) of medium on day 2 after passage, followed by two consecutive skipped days of feeds, with a final single-volume feed (2 mL) on day 5, prior to passaging on day 6 or 7.

hPSCs Maintained in TeSR™-AOF with Daily and Restricted Feed Schedules have Comparable Expansion Rates

Figure 1B. hPSCs Maintained in TeSR™-AOF with Daily and Restricted Feed Schedules have Comparable Expansion Rates

hPSCs were maintained on Vitronectin XF™ for five passages. At the end of each passage cell counts were obtained using the Nucleocounter®️ NC-200 ChemoMetec automated cell counter to count DAPI-stained nuclei. The log2 transformed cumulative fold expansion was plotted against time in culture (days).

Native bFGF Levels are Stabilized at 37°C in TeSR™-AOF

Figure 2. Native bFGF Levels are Stabilized at 37°C in TeSR™-AOF

TeSR™-AOF and TeSR™-E8™ were incubated at 37°C for 24, 48, and 72 hours. FGF2 levels were measured by Meso Scale Discovery (MSD) immunoassay; data was normalized to t = 0 levels for TeSR™-E8™ and TeSR™-AOF, respectively. FGF2 levels in TeSR™-AOF remain at 36.7 ± 5.61% of t = 0 levels at 72 hours when incubated at 37°C. Data representative of n = 3 biological replicates ± SD.

hPSCs Cultured in TeSR™-AOF with Restricted Feeding Maintain Demonstrate Classic hPSC Colony Morphology

Figure 3. hPSCs Cultured in TeSR™-AOF with Restricted Feeding Maintain Demonstrate Classic hPSC Colony Morphology

hPSCs maintained in TeSR™-AOF were passaged as aggregates with ReLeSR™ passaging reagent every 6-7 days for greater than 10 passages. hPSCs maintained in TeSR™-AOF exhibit hPSC-like morphology, forming densely packed, round colonies with smooth edge morphology. Homogeneous cell morphology characteristic of hPSCs are observed, including large nucleoli and scant cytoplasm.

hPSCs Maintained in TeSR™-AOF Have Improved Attachment and Higher Overall Expansion Compared to Low-Protein Medium

Figure 4. hPSCs Maintained in TeSR™-AOF Have Improved Attachment and Higher Overall Expansion Compared to Low-Protein Medium

(A) hPSCs cultured in TeSR™-AOF demonstrate a higher plating efficiency compared to hPSCs maintained in low-protein medium (TeSR™-E8™). Plating efficiency is calculated by seeding a known number of aggregates and comparing to the number of established colonies on day 7. (B) hPSCs maintained in TeSR™-AOF exhibit a higher average fold expansion per passage compared to TeSR™-E8™. (C) hPSCs cultured in TeSR™-AOF demonstrate consistent expansion and minimal cell line-to-cell-line variability between ES and iPS cell lines assessed. Cumulative fold expansion was measured from passage 1 to 5. Data represented as mean plating efficiency or fold expansion across 10 passages ± SD. MG = Matrigel®; VN = Vitronectin XF™.

hPSCs Cultured in TeSR™-AOF with Restricted Feeding Maintain a Normal Karyotype

Figure 5. hPSCs Cultured in TeSR™-AOF with Restricted Feeding Maintain a Normal Karyotype

ES (H9 & H1) and iPS (STiPS-M001 & STiPS-F016) cell lines cultured in TeSR™-AOF were screened for chromosomal abnormalities using the hPSC Genetic Analysis Kit and by G-banding at ≥ 10 passages. Representative data are shown for (A) H1 ES and STiPS-F016 hiPS cell cultures at passage 10; no common chromosomal abnormalities were detected using the hPSC Genetic Analysis Kit, and (B) H1 ES cultures; these displayed a normal karyotype by G-banding at passage 11 and 13 respectively.

hPSCs Cultured in TeSR™-AOF Express Markers of the Undifferentiated State and Differentiate to the Three Germ Layers

Figure 6. hPSCs Cultured in TeSR™-AOF Express Markers of the Undifferentiated State and Differentiate to the Three Germ Layers

(A) hPSCs maintained in TeSR™-AOF exhibit high levels of TRA-1-60 and OCT4 by flow cytometry at passage 5 and 10. Across n = 5 cell lines, the average TRA-1-60 expression was 92.8 ± 3.77 %, and percent OCT-4 positive cells were 98.1 ± 1.79%. Data shown represent an average of passage 5 and 10 flow results for each cell line. MG = Matrigel®; VN = Vitronectin XF™. (B) Efficient differentiation to the three germ layers was demonstrated in one hES and one hiPS cell line maintained for > 5 passages in TeSR™-AOF. Cultures were processed for flow cytometry and assessed for CXCR4+/SOX17+ cells on day 5 following differentiation using the STEMdiff™ Definitive Endoderm Kit. Cultures were processed for flow cytometry and assessed for Brachyury (T)+/OCT4- cells on day 5 following differentiation in STEMdiff™ Mesoderm Induction Medium. Cultures were processed for flow cytometry and assessed for PAX6+/Nestin+ cells on day 7 following monolayer differentiation using STEMdiff™ Neural Induction Medium.

hPSCs Culture in TeSR™-AOF Differentiate to Cardiomyocytes with the STEMdiff™ Cardiomyocyte Differentiation Kit

Figure 7. hPSCs Culture in TeSR™-AOF Differentiate to Cardiomyocytes with the STEMdiff™ Cardiomyocyte Differentiation Kit

Efficient differentiation to cardiomyocytes was demonstrated in 1 hES and 1 hiPS cell line maintained in TeSR™-AOF using the STEMdiff™ Cardiomyocyte Differentiation Kit. Expression of cardiac troponin T (cTnT) was assessed by immunocytochemistry (ICC) and by flow cytometry.

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.